当前位置: 首页 >> 检索结果
7201. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality.
7203. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
作者: Frances Humby.;Patrick Durez.;Maya H Buch.;Myles J Lewis.;Hasan Rizvi.;Felice Rivellese.;Alessandra Nerviani.;Giovanni Giorli.;Arti Mahto.;Carlomaurizio Montecucco.;Bernard Lauwerys.;Nora Ng.;Pauline Ho.;Michele Bombardieri.;Vasco C Romão.;Patrick Verschueren.;Stephen Kelly.;Pier Paolo Sainaghi.;Nagui Gendi.;Bhaskar Dasgupta.;Alberto Cauli.;Piero Reynolds.;Juan D Cañete.;Robert Moots.;Peter C Taylor.;Christopher J Edwards.;John Isaacs.;Peter Sasieni.;Ernest Choy.;Costantino Pitzalis.; .
来源: Lancet. 2021年397卷10271期305-317页
Although targeted biological treatments have transformed the outlook for patients with rheumatoid arthritis, 40% of patients show poor clinical response, which is mechanistically still unexplained. Because more than 50% of patients with rheumatoid arthritis have low or absent CD20 B cells-the target for rituximab-in the main disease tissue (joint synovium), we hypothesised that, in these patients, the IL-6 receptor inhibitor tocilizumab would be more effective. The aim of this trial was to compare the effect of tocilizumab with rituximab in patients with rheumatoid arthritis who had an inadequate response to anti-tumour necrosis factor (TNF) stratified for synovial B-cell status.
7204. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.
作者: Geltrude Mingrone.;Simona Panunzi.;Andrea De Gaetano.;Caterina Guidone.;Amerigo Iaconelli.;Esmeralda Capristo.;Ghassan Chamseddine.;Stefan R Bornstein.;Francesco Rubino.
来源: Lancet. 2021年397卷10271期293-304页
No data from randomised controlled trials of metabolic surgery for diabetes are available beyond 5 years of follow-up. We aimed to assess 10-year follow-up after surgery compared with medical therapy for the treatment of type 2 diabetes.
7205. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
作者: Stephanie Lheureux.;Mihaela C Cristea.;Jeffrey P Bruce.;Swati Garg.;Michael Cabanero.;Gina Mantia-Smaldone.;Alexander B Olawaiye.;Susan L Ellard.;Johanne I Weberpals.;Andrea E Wahner Hendrickson.;Gini F Fleming.;Stephen Welch.;Neesha C Dhani.;Tracy Stockley.;Prisni Rath.;Katherine Karakasis.;Gemma N Jones.;Suzanne Jenkins.;Jaime Rodriguez-Canales.;Michael Tracy.;Qian Tan.;Valerie Bowering.;Smitha Udagani.;Lisa Wang.;Charles A Kunos.;Eric Chen.;Trevor J Pugh.;Amit M Oza.
来源: Lancet. 2021年397卷10271期281-292页
The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have shown preclinical synergy and promising activity in early phase clinical trials. We aimed to determine the efficacy of this combination in patients with ovarian cancer.
7214. Neuropathology associated with SARS-CoV-2 infection.
作者: Kristof Egervari.;Christian Thomas.;Johannes A Lobrinus.;Tanja Kuhlmann.;Wolfgang Brück.;Seth Love.;John F Crary.;Christine Stadelmann.;Werner Paulus.;Doron Merkler.
来源: Lancet. 2021年397卷10271期276-277页 |